A practical playbook for leaders who need a defensible baseline, one shipped quick win, and a 12-month roadmap before the first quarterly review.
The organization plans and funds on quarterly cadence, so your assessment must deliver on quarterly cadence.
A comprehensive enterprise discovery can always consume nine months. Most pharma R&D sponsors cannot wait nine months to make portfolio decisions. The 90-day frame turns assessment into decision support instead of open-ended research.
The core signal is not speed for its own sake. The signal is the ability to translate limited leadership attention into defendable evidence and fundable next actions.
Use existing community-governed frameworks instead of inventing custom rubrics.
Automatable, reproducible checks move maturity discussion from opinion to evidence.
Pharma-tested rollup instrument for asset and portfolio-level maturity views.
Operational guidance to convert gap findings into concrete treatments.
Rule: every maturity score should trace to a test result or a structured steward interview, not a subjective rating workshop.
Three 30-day phases, each with one sponsor-facing deliverable and one explicit hand-off.
Portfolio heat map, stewardship map, and 10–20% priority subset.
FAIR scorecard by asset and dimension, plus ranked gap register.
12-month dependency-sequenced roadmap and one shipped treatment.
Build a working register across discovery, translational, clinical, regulatory, safety, and CMC domains.
Capture minimum metadata for each asset: owner, system, primary use, downstream consumers, and regulatory binding. Then map the decision reality: system owner, data owner, and funder are usually different people.
Deliver a heat map that surfaces trade-offs. The heat map is the first sponsor artifact and determines which assets enter Phase 2 measurement scope.
Run automation where possible, then add structured steward interviews for what automation cannot capture.
Generate objective maturity signals for resolvable assets and identify weakest sub-principles at scale.
Capture license clarity, provenance detail, and community-standard conformance gaps in a fixed template.
Layer CDISC, IDMP, MedDRA, RxNorm, UNII and GxP relevance to prioritize fundable treatments.
Per-asset scores, per-dimension portfolio metrics, and ranked remediation backlog with cost bands.
Sequence by dependency, not by largest score gap, and ship one treatment before Day 90 closes.
Start with enablers: persistent identifiers, controlled vocabularies, and provenance substrate. Then scale catalog ingestion and conformance treatment. This order compounds value and avoids local optimizations that do not travel.
Quick wins should be treatment artifacts, not dashboards. A promoted priority asset, remediated ontology criticals, or a live identifier resolver all qualify.
Deliverable standard: by Day 90, the sponsor should have a scorecard, gap register, roadmap, quick-win artifact, and governance recommendation.
Most failures come from scope and operating mistakes, not from framework choice.
Trying to score every asset before shipping anything guarantees a Day-90 miss.
Selecting catalog tooling before gap definition creates licenses without content strategy.
Visualizing maturity without shipping treatment does not improve maturity.
The 90-day assessment is the input to product mastering, semantic layer rollout, agentic curation, and ISO/IEC 23894 operationalization.
The maturity baseline determines sequencing across your next architecture phases. What changes after Day 90 is not the need for assessment; it is the shift from diagnosis to compounding treatment.
The value of a 90-day playbook is discipline: every claim traceable, every score reproducible, every roadmap line linked to evidence, and one concrete treatment shipped before the first quarterly review.
Diagnose in 30. Measure in 30. Ship in 30. Then the architecture.
Core sources include FAIR maturity frameworks, ontology governance, pharma quality risk guidance, and catalog operating standards.